SCHEMBL2393464

SCHEMBL2393464

CNC(=O)CN[C@H]1CC[C@H](CN(C)c2ccc(I)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 2/20 0.41
MDM4 O15151 1/20 0.41
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TRPV1 Q8NER1 1/20 0.34
KDM4C Q9H3R0 1/20 0.32
APOL1 O14791 1/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CXCR3 P49682 1/20 0.30
FASN P49327 1/20 0.30
JAK2 O60674 1/20 0.30
JAK1 P23458 1/20 0.30
TYK2 P29597 1/20 0.30
JAK3 P52333 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393466 1.00 MDM2 (0.41) MDM2MDM4MEN1KMT2ATRPV1
SCHEMBL2393193 0.85 MDM2 (0.34) MDM2MDM4MEN1KMT2ATRPV1
SCHEMBL2393190 0.85 MDM2 (0.34) MDM2MDM4MEN1KMT2ATRPV1
SCHEMBL2390604 0.83 MDM4 (0.39) MDM2MDM4MEN1KMT2A
SCHEMBL2390600 0.83 MDM4 (0.39) MDM2MDM4MEN1KMT2A
SCHEMBL23832500 0.80 EPHX2 (0.37) MDM2MEN1KMT2ATRPV1KDM4C
SCHEMBL12258078 0.77 MELK (0.33) MDM2MDM4MEN1KMT2AAPOL1
SCHEMBL2391106 0.74 MDM4 (0.36) MDM2MDM4MEN1KMT2A
SCHEMBL2391108 0.74 MDM4 (0.36) MDM2MDM4MEN1KMT2A
SCHEMBL2395843 0.74 SLC6A3 (0.40) TRPV1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051279-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2015-06-09 US disclosed
US-9051279-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2015-06-09 US disclosed
EP-2516009-B1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES NOVARTIS AG (CH) 2014-09-24 EP disclosed
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES NOVARTIS AG (CH) 2013-10-24 US disclosed
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES NOVARTIS AG (CH) 2013-10-24 US disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 US disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 US disclosed
EP-2516009-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES Novartis AG (CH) 2012-10-31 EP disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones MDM4, MDM2, TP53 MDM2 2/4885MDM4 1/4885MEN1 385/4885
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES MDM4, MDM2, TP53 MDM2 2/4885MDM4 1/4885MEN1 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.